September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Contralateral investigation of postoperative refractive surgery inflammation: Small-incision Lenticule Extraction vs LASIK.
Author Affiliations & Notes
  • Marianthi Stergiou Eye Institute, Athens, Greece
  • A. John Kanellopoulos Eye Institute, Athens, Greece
    Ophthalmology, NYU Medical School, NY, New York, United States
  • George Asimellis Eye Institute, Athens, Greece
    Kentucky College of Optometry, Pikeville, Kentucky, United States
  • Footnotes
    Commercial Relationships   Marianthi Stergiou, None; A. Kanellopoulos, Allergan (C), Avedro (C), i-Optics (C), ISP Surgical (C), Keramed (C); George Asimellis, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3874. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marianthi Stergiou, A. John Kanellopoulos, George Asimellis; Contralateral investigation of postoperative refractive surgery inflammation: Small-incision Lenticule Extraction vs LASIK.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3874.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : The purpose of this study was to comparative investigate potential impact of inflammation following myopic correction. The established current gold standard of femtosecond-assisted LASIK was compared to an all femto-second laser Small Incision refractive Lenticule Extraction (SMILE). No study has investigated the potential differences between SMILE and LASIK from the stand-point of postoperative inflammation.

Methods : This is a contralateral, perspective stud employing 10 consecutive myopic patients, in which one eye (group-A) was treated with the SMILE, while the other eye (group-B) with LASIK. The LASIK procedure employed the Alcon Refractive surgery platform (Alcon Surgical, Ft. Worth, TX) comprised of the FS200 femtosecond and the EX500 excimer laser. The SMILE procedure employed the 500 kHz VisuMax® femtosecond laser (Carl Zeiss Meditec AG, Jena, Germany).
InflammaDry (Rapid Pathogen Screening, Inc., Sarasota, FL) is an in-office test that detects matrix metalloproteinase MMP-9, an inflammatory marker that is consistently elevated in the tears of patients with dry eye disease. Using direct sampling microfiltration technology, InflammaDry identifies elevated levels of MMP-9 protein in tear fluid samples taken from the palpebral conjunctiva. Levels of MMP-9 were tested 1-month, 3-months and 6-months postoperatively, facilitated with the use of InflammaDry solution. Inclusion criteria: 18 years of age or older. Exclusion Criteria: Allergy to cornstarch or Darcon, Allergy to topical anesthetic or fluorescein dye.

Results : MMP-9 levels in group-A (LASIK) were 65±15 ng/ml, 55±12 ng/ml, 45±9 ng/ml at 1-, 3-, and 6- months, respectively. MMP-9 levels in group-B (SMILE) were 45±13 ng/ml, 42±12 ng/ml, 37±8 ng/ml at 1-, 3-, and 6- months, respectively. All groups displayed statistically significant differences at the perspective follow-up periods examined.

Conclusions : Potential differences between LASIK and SMILE include increased inflammation levels postoperatively up to 6 months.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.